CD14 and melanoma: For example, an increased frequency of circulating CD14+CD16−HLA-DRhi monocytes prior to treatment, along with a decreased frequency of T cells, correlate with survival and response to anti-PD-1 in melanoma patients (Krieg et al., 2018).